<unk> , sold under the brand names Trikafta (US) and Kaftrio (Europe), is a fixed-dose combination medication used in adults and children older than age 6 who have cystic fibrosis with a f508del mutation or other mutations. Patients with cystic fibrosis have thicker mucus secretions due to genetic mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein which inhibits the transfer of chloride and sodium ions from cells.<unk>  is composed of a combination of ivacaftor, a chloride channel opener, and<unk>  and<unk> , CFTR modulators. It is approved use in the United States for people aged 6 years of age or older with the f508del mutation or 177 other cystic fibrosis mutations. It is also approved for use in Canada, the European Union and Australia.
Elexacaftor/tezacaftor/ivacaftor
Lumacaftor/ivacaftor
Beclometasone/formoterol/glycopyrronium bromide
Lifitegrast
Mometasone/formoterol
Beclometasone/formoterol
Budesonide/formoterol
Aclidinium bromide/formoterol